Biocon signs licensing pact with Quark Pharma
The agreement is for developing a range of siRNA (small interfering RNA) based novel therapeutics.
New Delhi, December 18, 2013: Indian biotechnology company Biocon has signed an agreement with US-based Quark Pharmaceuticals Inc. to develop a range of siRNA (small interfering RNA) based novel therapeutics.
Biocon said in a statement that the collaboration will help the Indian company to co-develop, manufacture and commercialise QPI-1007, a novel siRNA drug candidate for ophthalmic conditions, for India and other key markets.
As part of the agreement, the deal will give Biocon access to Quark’s innovative and proprietary siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs.
The Indian company hopes to use this technology for developing several other novel therapeutics. QuarkPharma CEO Daniel Zurr said the collaboration will position Biocon as the leading siRNA company in India and as an international player in this new drug category.